Day: May 16, 2025

BASE SHELF PROSPECTUS ACCESSIBLE AND PROSPECTUS SUPPLEMENT TO BE ACCESSIBLE WITHIN TWO BUSINESS DAYS OF THE ANNOUNCEMENT OF THE OFFERING ON SEDAR+ NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, May 16, 2025 (GLOBE NEWSWIRE) — TerraVest Industries Inc. (TSX:TVK) (“TerraVest” or the “Company”) is pleased to announce, that as a result of strong investor demand, it has entered into a revised agreement to increase the size of its previously announced bought deal treasury offering. Under the revised agreement, the Company has agreed to sell, on a bought deal basis, 1,740,000 common shares (the “Shares”) from treasury to a syndicate of underwriters (the “Underwriters”) with National Bank Financial Markets, Canaccord Genuity, and Desjardins Capital Markets acting as Co-Bookrunners. The...

GARDENA, CA, May 16, 2025 (GLOBE NEWSWIRE) — Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the three months ended March 31, 2025. Q1 2025 Financial Highlights● Net sales were $1.7 million, compared to $1.7 million in the same period last year● Gross profit increased to $320,000, or 18.6% of sales, representing an improvement of 180% from a gross loss of $402,000, or (22.6)% of sales, in the same period last year● Operating expenses declined 10% to $1.4 million, compared to $1.5 million in the same period last year● Net loss declined $877,000 to $1.2 million, or $(0.50) per basic and diluted share, representing an improvement of 41% from a net loss of $2.1 million, or $(0.85) per basic and diluted...

Singapore, May 16, 2025 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it has begun exclusive negotiations for a US$1 billion BTC acquisition that will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion. This is a major strategic financial initiative to strengthen its balance sheet and support its aggressive expansion across Asia’s high-growth healthcare markets. Strategic Financial Restructuring for Growth BMGL is in advanced discussions with a consortium of institutional investors and high-net-worth individuals, who are influential in the crypto space, to acquire a US$1 billion BTC through an innovative share-swap arrangement. Management believes that this landmark transaction, if successful, will represent one...

DALLAS, May 16, 2025 (GLOBE NEWSWIRE) — Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insights into the severity of drug use and behavioral risk patterns. “Being recognized as the most innovative drug testing company of the year is a powerful validation of our team’s commitment to science, research, and client success,” said Brian Hullinger, President and CEO of Psychemedics. “Innovation is at the core...

PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. Poster Content: Interpreting Clinical Meaningfulness of SP-102 for the Treatment of Lumbosacral Radicular...

LOS ANGELES, May 16, 2025 (GLOBE NEWSWIRE) —  Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”) today reported its financial results for the first quarter ended March 31, 2025. Financial Results for First Quarter Ended March 31, 2025 Revenue was $2.8 million for the first quarter of 2025, which increased from $0.7 million during the same period of 2024. Increased revenue is attributable to new contracts in the Fiber Optics, Water Service Lines (Element 82), and Water Intake Solutions (Slant Well) businesses. Gross margin/(loss) was ($1.0) million for the first quarter of 2025, compared to gross margin/(loss) of ($1.0) million during the same period of 2024. Operating expenses were approximately $8.9 million for the first quarter of 2025, up from $2.7 million during the same period of 2024. Net...